Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria:

1. Newly diagnosed untreated acute myeloid leukemia patients;
2. Age range from 18 to 75 years old;
3. The Eastern Cooperative oncology Group (ECOG) score is ≤ 2 points;
4. The following organ functional conditions must be met:

   * Liver function (bilirubin\<2mg/dL, AST and/or ALT\<3 x ULN)
   * Renal function (blood creatinine clearance rate ≥ 30 mL/min)
   * Cardiac function (left ventricular ejection fraction ≥ 50%)
5. If the age is ≥ 60 years old, the following conditions must be further met;

   * Charlson comorbidity index (CCI) ≤ 1
   * Activity of Daily Living Scale (ADL)\>100
   * No cognitive impairment, Mini Mental State Examination (MMSE) ≥ 28
   * No impairment of living ability, Short Physical Performance Battery Protocol (SPPB) ≥ 9
6. Women with fertility must have a negative serum pregnancy test ≤ 7 days before the first administration. In addition, they must use efficient contraceptive methods before the first dose of study medication, during the study treatment period, and for ≥ 180 days after the last dose of study medication.
7. Non infertile males must use efficient contraceptive methods during the study treatment period and within ≥ 90 days after the last dose of the study medication. During this period, they are not allowed to donate sperm.
8. The patient fully understands this study, obtains an informed consent form (ICF) signed by the patient or their legal representative, and follows the research protocol and follow-up process.
9. The expected lifespan is greater than 12 weeks.

Exclusion Criteria:

1. Acute promyelocytic leukemia (APL)；
2. Malignant tumor in the past 2 years, except for cured localized skin cancer, superficial bladder cancer, cervical cancer or cancer in situ of breast cancer, and localized prostate cancer with Gleason score ≤ 6;
3. Uncontrolled concurrent diseases, including but not limited to: ongoing or active uncontrolled infections, cardiovascular or mental illnesses/social situations that may limit compliance with research requirements;
4. It is known that the subjects are positive for hepatitis B or hepatitis C infection, except those whose viral load cannot be detected within 3 months (Note: patients with HBcAb+but HBsAg - can only meet the condition if hepatitis B virus (HBV) DNA cannot be detected in the detection with sensitivity ≤ 20 IU/mL. In this case, patients should receive regular monitoring of HBV DNA and receive prophylactic antiviral drug treatment according to the central diagnosis and treatment routine; Patients with HCV antibody+are eligible only if they cannot detect HCV RNA and are willing to monitor HCV reactivation；
5. Receive any moderate or strong CYP3A4 inhibitor (7 days or 5 half-lives, whichever is longer) or moderate or strong CYP3A4 inducer (14 days or 5 half-lives, whichever is longer) treatment before the first use of Sonrotoclax；
6. Patients who are known to have hypersensitivity reactions to any component in the study protocol;
7. Known central nervous system involvement in AML;
8. Previously received organ, bone marrow, or peripheral blood organ transplantation；
9. Participate in another therapeutic clinical study simultaneously；
10. Pregnant or lactating women, or male and female patients planning to have children during the study period.